Moreover, the researcher evaluated the combination of the NKG2A antibody monalizumab and anti-EGFR antibody cetuximab in treating patients with squamous cell carcinoma of the head and neck, a type of cancer with strong expression of HLA-E. Here, KLRC1 is linked to cancer.